Tags

Type your tag names separated by a space and hit enter

Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Clin Endocrinol (Oxf) 2007; 66(2):282-9CE

Abstract

OBJECTIVE

We examined the individual pharmacological effects of the addition of rosiglitazone and metformin to glimepiride on inflammatory markers and adipokines in patients with type 2 diabetes mellitus. We analysed the relationships between these variables, the measurements of insulin sensitivity and beta-cell function in patients treated with rosiglitazone plus glimepiride.

DESIGN AND PATIENTS

One hundred twenty (120) patients with type 2 diabetes mellitus were randomized and treated with glimepiride plus rosiglitazone or glimepiride plus metformin for 12 weeks. The plasma concentrations of the inflammatory markers and adipokines were measured at baseline and after 12 weeks.

MEASUREMENTS

Markers of insulin sensitivity and beta-cell function were determined by the quantitative insulin sensitivity check index (QUICKI) and the homeostasis model assessment of beta-cell function (HOMA-beta), respectively. Plasma concentrations of adiponectin were measured by radioimmunoassay. Plasma concentrations of resistin, tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-18 (IL-18) were measured using ELISA.

RESULTS

Improvements in fasting insulin level, QUICKI and HOMA-beta were noted in the rosiglitazone-treated group. Only the QUICKI value improved in the metformin-treated group. Adiponectin concentrations significantly increased in the rosiglitazone-treated group after 12 weeks. Significant decreases in resistin, C-reactive protein, TNF-alpha, IL-6 and IL-18 were seen in the rosiglitazone-treated patients but not in the metformin-treated patients. The independent risk factor for the HOMA-beta change according to stepwise multivariate regression analysis was a change in IL-18.

CONCLUSIONS

Rosiglitazone, but not metformin, improved the plasma concentrations of inflammatory markers and adipokines in patients with type 2 diabetes mellitus. A decrease in IL-18 is an independent factor for the improvement of HOMA-beta in type 2 diabetes mellitus.

Authors+Show Affiliations

Division of Endocrinology, Department of Internal Medicine, Kwandong University College of Medicine, Myongji Hospital, Koyang, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17224000

Citation

Kim, Hyeong Jin, et al. "Effects of Rosiglitazone and Metformin On Inflammatory Markers and Adipokines: Decrease in Interleukin-18 Is an Independent Factor for the Improvement of Homeostasis Model Assessment-beta in Type 2 Diabetes Mellitus." Clinical Endocrinology, vol. 66, no. 2, 2007, pp. 282-9.
Kim HJ, Kang ES, Kim DJ, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007;66(2):282-9.
Kim, H. J., Kang, E. S., Kim, D. J., Kim, S. H., Ahn, C. W., Cha, B. S., ... Lee, H. C. (2007). Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical Endocrinology, 66(2), pp. 282-9.
Kim HJ, et al. Effects of Rosiglitazone and Metformin On Inflammatory Markers and Adipokines: Decrease in Interleukin-18 Is an Independent Factor for the Improvement of Homeostasis Model Assessment-beta in Type 2 Diabetes Mellitus. Clin Endocrinol (Oxf). 2007;66(2):282-9. PubMed PMID: 17224000.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. AU - Kim,Hyeong Jin, AU - Kang,Eun Seok, AU - Kim,Dae Jung, AU - Kim,So Hun, AU - Ahn,Chul Woo, AU - Cha,Bong Soo, AU - Nam,Moonsuk, AU - Chung,Choon Hee, AU - Lee,Kwan Woo, AU - Nam,Chung Mo, AU - Lee,Hyun Chul, PY - 2007/1/17/pubmed PY - 2007/7/19/medline PY - 2007/1/17/entrez SP - 282 EP - 9 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 66 IS - 2 N2 - OBJECTIVE: We examined the individual pharmacological effects of the addition of rosiglitazone and metformin to glimepiride on inflammatory markers and adipokines in patients with type 2 diabetes mellitus. We analysed the relationships between these variables, the measurements of insulin sensitivity and beta-cell function in patients treated with rosiglitazone plus glimepiride. DESIGN AND PATIENTS: One hundred twenty (120) patients with type 2 diabetes mellitus were randomized and treated with glimepiride plus rosiglitazone or glimepiride plus metformin for 12 weeks. The plasma concentrations of the inflammatory markers and adipokines were measured at baseline and after 12 weeks. MEASUREMENTS: Markers of insulin sensitivity and beta-cell function were determined by the quantitative insulin sensitivity check index (QUICKI) and the homeostasis model assessment of beta-cell function (HOMA-beta), respectively. Plasma concentrations of adiponectin were measured by radioimmunoassay. Plasma concentrations of resistin, tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-18 (IL-18) were measured using ELISA. RESULTS: Improvements in fasting insulin level, QUICKI and HOMA-beta were noted in the rosiglitazone-treated group. Only the QUICKI value improved in the metformin-treated group. Adiponectin concentrations significantly increased in the rosiglitazone-treated group after 12 weeks. Significant decreases in resistin, C-reactive protein, TNF-alpha, IL-6 and IL-18 were seen in the rosiglitazone-treated patients but not in the metformin-treated patients. The independent risk factor for the HOMA-beta change according to stepwise multivariate regression analysis was a change in IL-18. CONCLUSIONS: Rosiglitazone, but not metformin, improved the plasma concentrations of inflammatory markers and adipokines in patients with type 2 diabetes mellitus. A decrease in IL-18 is an independent factor for the improvement of HOMA-beta in type 2 diabetes mellitus. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/17224000/Effects_of_rosiglitazone_and_metformin_on_inflammatory_markers_and_adipokines:_decrease_in_interleukin_18_is_an_independent_factor_for_the_improvement_of_homeostasis_model_assessment_beta_in_type_2_diabetes_mellitus_ L2 - https://doi.org/10.1111/j.1365-2265.2006.02723.x DB - PRIME DP - Unbound Medicine ER -